Working Groups

//
Working Groups
Working Group 1

WG1 - Study Populations and Expertise Groups

The objective of this Working Group is to create, maintain an update the studies and group of experts conforming the network. The European research groups will be central to these organizations but will also reach to an international setting in the Americas and Australasian regions, procuring to maximize the enrichment of the network.
Working Group 2

WG2 – Phenotyping

The objective of this Working Group will be to describe ways to decompose the phenotypes of the different genetic studies into meaningful components that will aid the interpretation of the identified biological pathways.
Working Group 3

WG3 – Monogenic Conditions- human KO Models

The objective of this Working Group up will initially be to make an inventory of all the genes underlying monogenic conditions presenting with a clear musculoskeletal phenotype. After this, the main focus of WG5 will be to evaluate the overlap between this list of genes and those genes characterized by WG4 and trace them back into common biological pathways.
Working Group 4

WG4 – Functional Investigations

The objective of this Working Group is to initially liaise with WG1 to make an inventory of the expertise across functional groups of the network with a trajectory on “wet lab” cell and organism models of the musculoskeletal system.
Working Group 5

WG5 – Bioinformatics

The objective of this Working Group will initially be to make an inventory of all the genetic discoveries arising from the distinct efforts. This will be followed by the integration of databases and resources from the public domain, but also those assembled from the different functional Working Groups of the network as inventoried by WG2.
Working Group 6

WG6 – Translational Outreach

The objective of this Working Group is to make a synopsis of the knowledge derived from the integration of activities and expertise provided by WG1, WG2, WG3, WG4 and WG5. In order to constitute a roadmap for the identification of drug targets by means of pinpointing molecules and factors within biological pathways that can be suitable for future investigations in a potential therapeutic context.

Participants

Aare Märtson
Estonia
Alban Ylli
Albania
Aleksandra Nikolic
Serbia
Alice Costantini
Sweden
Alper Cebi
Turkey
Amina Valjevac
Bosnia and Herzegovina
Ana VASIC
Serbia
Anastasios Bezerianos
Greece
Anastasis Stephanou
Cyprus
Anders Kämpe
Sweden
André Uitterlinden
Netherlands
Angela Xuereb-Anastai
Malta
Angeles Morales Fernández
Spain
Ângelo Calado
Portugal
Anna Teti
Italy
Antonia Sophocleous
Cyprus
Antonio Maurizi
Italy
Åshild Bjørnerem
Norway
Barbara OBERMAYER-PIETSCH
Austria
Barbara Ostanek
Slovenia
Barbara Voraberger
Austria
Bayram Bayramov
Azerbaijan
Beatriz Larraz Prieto
Spain
Bendik Winsvold
Bente Langdahl
Denmark
Bert van Rietbergen
Netherlands
Björn Busse
Germany
Bledar Kraja
Albania
Bodhisattwa Banerjee